IBDEI1A8 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21807,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,21808,0)
 ;;=L40.4^^87^970^157
 ;;^UTILITY(U,$J,358.3,21808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21808,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,21808,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,21808,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,21809,0)
 ;;=L40.8^^87^970^252
 ;;^UTILITY(U,$J,358.3,21809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21809,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,21809,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,21809,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,21810,0)
 ;;=L40.9^^87^970^254
 ;;^UTILITY(U,$J,358.3,21810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21810,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,21810,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,21810,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,21811,0)
 ;;=L50.9^^87^970^286
 ;;^UTILITY(U,$J,358.3,21811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21811,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,21811,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,21811,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,21812,0)
 ;;=L53.8^^87^970^147
 ;;^UTILITY(U,$J,358.3,21812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21812,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,21812,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,21812,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,21813,0)
 ;;=L53.9^^87^970^146
 ;;^UTILITY(U,$J,358.3,21813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21813,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,21813,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,21813,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,21814,0)
 ;;=L54.^^87^970^145
 ;;^UTILITY(U,$J,358.3,21814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21814,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,21814,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,21814,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,21815,0)
 ;;=L56.0^^87^970^139
 ;;^UTILITY(U,$J,358.3,21815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21815,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,21815,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,21815,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,21816,0)
 ;;=L56.1^^87^970^138
 ;;^UTILITY(U,$J,358.3,21816,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21816,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,21816,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,21816,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,21817,0)
 ;;=L56.2^^87^970^236
 ;;^UTILITY(U,$J,358.3,21817,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21817,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,21817,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,21817,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,21818,0)
 ;;=L56.3^^87^970^268
 ;;^UTILITY(U,$J,358.3,21818,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21818,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,21818,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,21818,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,21819,0)
 ;;=L57.0^^87^970^12
 ;;^UTILITY(U,$J,358.3,21819,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21819,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,21819,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,21819,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,21820,0)
 ;;=L60.0^^87^970^161
 ;;^UTILITY(U,$J,358.3,21820,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21820,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,21820,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,21820,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,21821,0)
 ;;=L60.1^^87^970^234
 ;;^UTILITY(U,$J,358.3,21821,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21821,1,3,0)
 ;;=3^Onycholysis
